Share this @internewscast.com
The team also looked at COX-2 inhibitors, a new generation anti-inflammatory drug.
To evaluate the effects of both drugs, researchers analysed randomised control trials comparing NSAID, with other forms of the anti-inflammatory pill or placebo.
A total of thirty-one trials were completed, with 116,429 patients involved.
The results revealed that rofecoxib and lumiracoxib were associated with twice the risk of heart attack when compared with placebo.
Source: Daily Express